Global Cancer Immunotherapy Market & Clinical Tria

Dublin, May 01, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022" report to their offering. Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022 report gives comprehensive insight on clinical and non-clinical developments in the field of cancer immunotherapy. As per report findings, cancer immunotherapy has emerged as the new growth frontier for the pharmaceutical companies involved in the clinical research and development of cancer drugs and therapeutics. Currently there are more than 2000 cancer immunotherapies based drugs/therapies are in clinical pipeline. Majority of these are in preclinical, Phase-I and Phase-II trials. There are 14 cancer vaccine, 44 Cancer monoclonal antibodies, 3 cancer cell therapies and 61 cancer Immunomodulators are commercially available in the market. Pharmaceutical companies are actively engaged in research and development of cancer immunotherapies because of large unmet medical necessities. Investigators are trying to come forth with innovative cancer immunotherapeutic products having high safety and efficacy profiles which are not offered by conventional therapeutics. Higher investments in research and development segment could significantly increase the drug discovery rates which will alleviate the medical condition of cancer patients. Simultaneously, technological advancements are being made due to which development of worthy candidates with high commercialization and pharmacological potential is expected to increase in coming years. Investigators are trying to decipher underlying principle of cancer progression and proliferation. Different cancer indications have different requirements for developing effective therapeutics due to which identification of these factors have become important. This knowledge would be used for developing innovative cancer immunotherapies for various malignancies. Cancer immunotherapeutics based on these discoveries would pave path for market introduction of highly effective therapeutics. Some progress has been made which could be noticed by observing plethora of cancer immunotherapeutics available for different cancer indications. Their clinical pipeline is also developing rapidly and various products are at different stages of clinical trials. They are expected to offer severe competition to presently available cancer therapeutics with modest pharmacological efficacy. Cancer immunotherapies have been used for limited number of malignancies as compared to other drug categories. Mostly hematological malignancies like follicular lymphoma, chronic lymphocytic leukemia and diffuse large B cell non-Hodgkin's lymphoma have remained the focal point. Other cancer indications like melanoma, NSCLC, prostate cancer and RCC have also got cancer immunotherapeutics. Most like, cancer therapeutics in clinical trials would be able to present positive data that will allow them to easily enter in global market. Cancer incidences are escalating rapidly and cancer immuno therapeutics seems to play an important role in offering better medical care to patients. Some of them have received FDA's accelerated approval and breakthrough therapy designation due to their superior pharmacological benefits. It is expected that similar progress would be shown by cancer immunotherapeutics under development for different malignancies. - Competitive Analysis Key Topics Covered: 1. Immunotherapy: Mending Cancer Regimens 1.1 Preface to Cancer Immunotherapy 1.2 Evolution of Cancer Immunotherapy 2. Categorization of Cancer Immunotherapy 2.1 Specific Cancer Immunotherapy 2.1.1 Cancer Vaccines 2.1.2 Monoclonal Antibodies 2.2 Non-Specific Cancer Immunotherapy 2.2.1 Adoptive Cell Transfer Immunotherapy 2.2.2 Immune Checkpoint Inhibitors 3. Fundamentals of Cancer Vaccines 3.1 Prologue of Cancer Vaccines 3.2 Cancer Vaccines in Immunotherapy 3.3 Commercial Aspects of Cancer Vaccines 4. New Era of Monoclonal Antibodies 4.1 Rudiments of Monoclonal Antibodies 4.2 Advents of Monoclonal Antibodies 4.3 Commercial Aspects of Monoclonal Antibodies 5. Trails of T-Cell Therapies 5.1 Adoptive Cell Transfer Technology 5.2 Strategies of Adoptive Cell Transfer 5.3 Commercial Aspects of Adoptive Cell Therapy 6. Aspects of Immune Checkpoint Inhibitors 6.1 Prelude to Immune Checkpoint Inhibitors 6.2 Implications of Immunecheck Point Inhibitors 6.3 Commercial Aspects of Immune Checkpoint Inhibitors 7. Immunomodulators in Cancer Immunotherapy 7.1 Perspective of Immunomodulators 7.2 Clinical Aspects of Immunomodulators 7.3 Commercial Aspects of Immunomodulators 8. Oncolytic Viral Immunotherapy 8.1 Concept to Oncolytic Viruses 8.2 Potential Approaches of Oncolytic Viruses 8.3 Commercial Aspects of Oncolytic Viruses 9. Cytokines in Cancer Immunotherapy 9.1 Fundamentals of Cytokines 9.2 Classification of Cytokines 9.3 Commercial Aspects of Cytokines 10. Interferons in Immunotherapy 10.1 Potentials of Interferons 10.2 Classification of Interferons 10.3 Clinical Applications of Interferons 11. Interleukins in Immunotherapy 11.1 Potentials of Interleukins 11.2 Clinical Applications of Interleukins 12. GM-CSF in Immunotherapy 12.1 Potentials of GM-CSF 12.2 Clinical Applications of GM-CSF 13. Global Economic Evaluations 13.1 Economic Aspects of Cancer Immunotherapy 13.2 Cancer Immunotherapy Cost by Product 14. Market Aspects of Cancer Immunotherapy 14.1 Current Market Trends 14.2 Cancer Immunotherapy Pipeline Overview 15. Global Cancer Immunotherapy Market Dynamics 15.1 Favorable Market Parameters 15.2 Commercialization Challenges 16. Marketed Cancer Cell Therapies Drugs 16.1 Sipuleucel-T (Provenge®) 16.2 T-Lymphocyte Cell Therapy(Immuncell-LC®) 17. Marketed Cancer Cytokines Drugs 17.1 Aldesleukin (Proleukin®) 17.2 Denileukin Diftitox (ONTAK®) 17.3 Interferon Alpha (Multiferon®) 17.4 Interferon Alpha-2a (Roferon-A®) 17.5 Interferon Alpha-2a (Veldona®) 17.6 Interferon Alpha-2a Biosimilar(Inferon/Inmutag) 17.7 Interferon Alpha-2b(Intron® A) 17.8 Interferon Alpha-2b Biosimilar(Bioferon) 17.9 Interferon Alpha-2b Biosimilar (Intalfa®) 17.10 Interferon Alpha-2b Biosimilar 17.11 Interferon-Alpha-n3 (Alferon N®) 17.12 Interferon-Beta-1b (Feron®) 17.13 Interferon-Gamma (Ogamma®) 17.14 Interleukin-2 Biosimilar (Ilcass) 17.15 Teceleukin (Imunace) 18. Marketed Cancer Vaccines 18.1 Bladder Cancer Vaccine (PACIS®) 18.2 Bladder Cancer Vaccine 18.3 BV NSCLC 001 18.4 Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®) 18.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®) 18.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®) 18.7 Melanoma Vaccine (MVax®) 18.8 Melanoma Vaccine (Melacine®) 18.9 Racotumomab (Vaxira®) 18.10 Sipuleucel-T (Provenge®) 18.11 Tertomotide (LucaVax) 18.12 Vitespen (Oncophage®) 19. Marketed Cancer Monoclonal Antibodies 19.1 Bevacizumab 19.2 Trastuzumab Emtansine 19.3 Trastuzumab Subcutaneous 19.4 Brentuximab Vedotin 19.5 Catumaxomab 19.6 Ipilimumab 19.7 Nivolumab 19.8 Pembrolizumab 19.9 Pertuzumab 19.10 Rituximab 19.11 Trastuzumab 20. Global Cancer Immunotherapy Market Future Prospects 21. Competitive Landscape 21.1 Abbvie 21.2 Advaxis 21.3 Altor BioScience 21.4 Amgen 21.5 Biogen Idec 21.6 Biogenomics 21.7 Celldex Therapeutics 21.8 Dendreon Corporation 21.9 Eli Lilly 21.10 Expression Genetics 21.11 Galena Biopharma 21.12 Genmab 21.13 Gilead Sciences 21.14 GlaxoSmithKline 21.15 ImmunoCellular Therapeutics 21.16 ImmunoGen 21.17 Inovio Pharmaceuticals 21.18 IRX Therapeutics 21.19 Merck 21.20 NeoStem Oncology 21.21 NewLink Genetics 21.22 Northwest Biotherapeutics 21.23 Novartis 21.24 Peregrine Pharmaceuticals 21.25 Pfizer 21.26 Philogen 21.27 Regulon 21.28 Roche 21.29 Seattle Genetics 21.30 ZymoGenetics For more information about this report visit http://www.researchandmarkets.com/research/rl...bal_cancer

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Oncology Drugs , Clinical Trials